Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

v3.21.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)    
Revenues, net $ 10,124 $ 36,895
Operating expenses:    
Cost of implants and other costs 632 22,934
Research and development 658,237 710,570
Selling, general and administrative 911,093 801,946
Depreciation and amortization 19,378 19,171
Total operating expenses 1,589,340 1,554,561
Loss from operations (1,579,216) (1,517,666)
Other income (expenses):    
Interest expense, net (123,308) (125,407)
Grant income 90,232 564,086
Other miscellaneous income 28,229 799
Total other income (expenses) (4,847) 439,478
Net loss before provision for income taxes (1,584,063) (1,078,188)
Income taxes 0 0
Net loss (1,584,063) (1,078,188)
Non-controlling interest 776 11,626
NET LOSS ATTRIBUTIBLE TO BIOCORRX, INC. $ (1,583,287) $ (1,066,562)
Net loss per common share, basic and diluted $ (0.26) $ (0.20)
Weighted average number of common shares outstanding, basic and diluted 6,018,763 5,335,054